REFERENCES
1. Zumsteg ZS, Luu M, Rosenberg PS, et al. Global epidemiologic patterns of oropharyngeal cancer incidence trends. J Natl Cancer Inst 2023;115:1544-54.
2. Zhang Y, Fakhry C, D’Souza G. Projected association of human papillomavirus vaccination with oropharynx cancer incidence in the US, 2020-2045. JAMA Oncol 2021;7:e212907.
3. Zevallos JP, Kramer JR, Sandulache VC, et al. National trends in oropharyngeal cancer incidence and survival within the veterans affairs health care system. Head Neck 2021;43:108-15.
4. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35.
5. Ferris RL, Flamand Y, Weinstein GS, et al. Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: an ECOG-ACRIN cancer research group trial (E3311). J Clin Oncol 2022;40:138-49.
6. Petrelli F, Nardone M, Trevisan F, et al. Comparison of different treatments for HPV+ oropharyngeal carcinoma: a network meta-analysis. Eur Arch Otorhinolaryngol 2023;280:963-71.
7. Lechner M, Liu J, Masterson L, Fenton TR. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol 2022;19:306-27.
8. Masroor F, Corpman D, Carpenter DM, Ritterman Weintraub M, Cheung KHN, Wang KH. Association of NCCN-recommended posttreatment surveillance with outcomes in patients with HPV-associated oropharyngeal squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg 2019;145:903-8.
9. Trosman SJ, Koyfman SA, Ward MC, et al. Effect of human papillomavirus on patterns of distant metastatic failure in oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. JAMA Otolaryngol Head Neck Surg 2015;141:457-62.
10. Huang SH, O’Sullivan B, Xu W, et al. Temporal nodal regression and regional control after primary radiation therapy for N2-N3 head-and-neck cancer stratified by HPV status. Int J Radiat Oncol Biol Phys 2013;87:1078-85.
11. Nekhlyudov L, Lacchetti C, Siu LL. Head and neck cancer survivorship care guideline: american society of clinical oncology clinical practice guideline endorsement summary. J Oncol Pract 2018;14:167-71.
12. Smith JD, Shuman AG, Riba MB. Psychosocial issues in patients with head and neck cancer: an updated review with a focus on clinical interventions. Curr Psychiatry Rep 2017;19:56.
13. De Luca P, Radici M, Camaioni A. The relationship between the upper aerodigestive tract microbiome axis and head and neck cancers: is it time to bet on it? Eur Arch Otorhinolaryngol 2023;280:4299-301.
14. Auger S, Davis A, Rosenberg AJ. Recommendations for care of survivors of head and neck cancer. JAMA 2022;328:1637-8.
15. National Comprehensive Cancer Network. Head and neck cancers. Available from: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf [Last accessed 18 Feb 2024].
16. Frakes JM, Naghavi AO, Demetriou SK, et al. Determining optimal follow-up in the management of human papillomavirus-positive oropharyngeal cancer. Cancer 2016;122:634-41.
17. Imbimbo M, Alfieri S, Botta L, et al. Surveillance of patients with head and neck cancer with an intensive clinical and radiologic follow-up. Otolaryngol Head Neck Surg 2019;161:635-42.
18. Gharzai LA, Burger N, Li P, et al. Patient burden with current surveillance paradigm and factors associated with interest in altered surveillance for early stage HPV-related oropharyngeal cancer. Oncologist 2021;26:676-84.
19. Kuhs KAL, Brenner JC, Holsinger FC, Rettig EM. Circulating tumor HPV DNA for surveillance of HPV-positive oropharyngeal squamous cell carcinoma: a narrative review. JAMA Oncol 2023;9:1716-24.
20. Hanna GJ, Roof SA, Jabalee J, et al. Negative predictive value of circulating tumor tissue modified viral (TTMV)-HPV DNA for HPV-driven oropharyngeal cancer surveillance. Clin Cancer Res 2023;29:4306-13.
21. Berger BM, Hanna GJ, Posner MR, et al. Detection of occult recurrence using circulating tumor tissue modified viral HPV DNA among patients treated for HPV-driven oropharyngeal carcinoma. Clin Cancer Res 2022;28:4292-301.
22. Cao Y, Haring CT, Brummel C, et al. Early HPV ctDNA kinetics and imaging biomarkers predict therapeutic response in p16+ oropharyngeal squamous cell carcinoma. Clin Cancer Res 2022;28:350-9.
23. Ferrandino RM, Chen S, Kappauf C, et al. Performance of liquid biopsy for diagnosis and surveillance of human papillomavirus-associated oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg 2023;149:971-7.
24. Haring CT, Brummel C, Bhambhani C, et al. Implementation of human papillomavirus circulating tumor DNA to identify recurrence during treatment de-escalation. Oral Oncol 2021;121:105332.
25. Haring CT, Bhambhani C, Brummel C, et al. Human papilloma virus circulating tumor DNA assay predicts treatment response in recurrent/metastatic head and neck squamous cell carcinoma. Oncotarget 2021;12:1214-29.
26. Allevato MM, Smith JD, Brenner MJ, Chinn SB. Tumor-derived exosomes and the role of liquid biopsy in human papillomavirus oropharyngeal squamous cell carcinoma. Cancer J 2023;29:230-7.
27. Xie DX, Kut C, Quon H, Seiwert TY, D’Souza G, Fakhry C. Clinical Uncertainties of circulating tumor DNA in human papillomavirus-related oropharyngeal squamous cell carcinoma in the absence of national comprehensive cancer network guidelines. J Clin Oncol 2023;41:2483-7.
28. Chera BS, Kumar S, Shen C, et al. Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer. J Clin Oncol 2020;38:1050-8.
29. Ward MC, Miller JA, Walker GV, Moeller BJ, Koyfman SA, Shah C. The economic impact of circulating tumor-tissue modified HPV DNA for the post-treatment surveillance of HPV-driven oropharyngeal cancer: a simulation. Oral Oncol 2022;126:105721.
30. Dermody SM, Bhambhani C, Swiecicki PL, Brenner JC, Tewari M. Trans-renal cell-free tumor DNA for urine-based liquid biopsy of cancer. Front Genet 2022;13:879108.
31. Ferrier ST, Tsering T, Sadeghi N, Zeitouni A, Burnier JV. Blood and saliva-derived ctDNA is a marker of residual disease after treatment and correlates with recurrence in human papillomavirus-associated head and neck cancer. Cancer Med 2023;12:15777-87.
32. Sandulache VC, Hamblin J, Lai S, et al. Oropharyngeal squamous cell carcinoma in the veteran population: association with traditional carcinogen exposure and poor clinical outcomes. Head Neck 2015;37:1246-53.
33. Feinstein AJ, Shay SG, Chang E, Lewis MS, Wang MB. Treatment outcomes in veterans with HPV-positive head and neck cancer. Am J Otolaryngol 2017;38:188-92.
34. Chidambaram S, Chang SH, Sandulache VC, Mazul AL, Zevallos JP. Human papillomavirus vaccination prevalence and disproportionate cancer burden among US veterans. JAMA Oncol 2023;9:712-4.
35. Sandulache VC, Lei YL, Heasley LE, et al. Innovations in risk-stratification and treatment of Veterans with oropharynx cancer; roadmap of the 2019 field based meeting. Oral Oncol 2020;102:104440.
36. Freeman VL, Durazo-Arvizu R, Arozullah AM, Keys LC. Determinants of mortality following a diagnosis of prostate cancer in veterans affairs and private sector health care systems. Am J Public Health 2003;93:1706-12.
37. Landrum MB, Keating NL, Lamont EB, et al. Survival of older patients with cancer in the veterans health administration versus fee-for-service medicare. J Clin Oncol 2012;30:1072-9.
38. Henry M, Rosberger Z, Bertrand L, et al. Prevalence and risk factors of suicidal ideation among patients with head and neck cancer: longitudinal study. Otolaryngol Head Neck Surg 2018;159:843-52.
39. Chew EY, Hartman CM, Richardson PA, et al. Risk factors for oropharynx cancer in a cohort of HIV-infected veterans. Oral Oncol 2017;68:60-6.
40. Mazul AL, Hartman C, Kramer J, et al. Incidence and survival for oropharynx and non-oropharynx head and neck cancers among veterans living with HIV. Cancer Med 2020;9:9326-35.
41. Mazul AL, Hartman CM, Mowery YM, et al. Risk and incidence of head and neck cancers in veterans living with HIV and matched HIV-negative veterans. Cancer 2022;128:3310-8.
42. Saxena K, Dawson RS, Cyhaniuk A, Bello T, Janjan N. Clinical and economic burden of HPV-related cancers in the US veteran population. J Med Econ 2022;25:299-308.
43. Shay SG, Chang E, Lewis MS, Wang MB. Characteristics of human papillomavirus-associated head and neck cancers in a veteran population. JAMA Otolaryngol Head Neck Surg 2015;141:790-6.
44. Shires CB, Tomeh C, Zafar N, Sebelik ME. Oropharyngeal squamous cell carcinoma outcomes by p16(INK4a) antigen status in a veteran population. Fed Pract 2023;40:S64-7.
45. Zevallos JP, Sandulache VC, Hamblin J, et al. Impact of race on oropharyngeal squamous cell carcinoma presentation and outcomes among veterans. Head Neck 2016;38:44-50.
46. Faraji F, Kumar A, Voora R, et al. Transoral surgery in HPV-positive oropharyngeal carcinoma: oncologic outcomes in the veterans affairs system. Laryngoscope 2024;134:207-14.
47. Nelson TJ, Thompson CA, Zou J, et al. Validation of NRG oncology’s prognostic nomograms for oropharyngeal cancer in the veterans affairs database. Cancer 2022;128:1948-57.
48. Richardson PA, Kansara S, Chen GG, et al. Treatment patterns in veterans with laryngeal and oropharyngeal cancer and impact on survival. Laryngoscope Investig Otolaryngol 2018;3:275-82.
49. Soliman O, Wilde DC, Kemnade JO, et al. Deployment of cisplatin in veterans with oropharyngeal cancer: toxicity and impact on oncologic outcomes. Laryngoscope Investig Otolaryngol 2023;8:895-902.
50. Nobel T, Rajupet S, Sigel K, Oliver K. Using veterans affairs medical center (VAMC) data to identify missed opportunities for HPV vaccination. Hum Vaccin Immunother 2019;15:1878-83.
51. Sandulache VC, Wilde DC, Sturgis EM, Chiao EY, Sikora AG. A hidden epidemic of “Intermediate risk” oropharynx cancer. Laryngoscope Investig Otolaryngol 2019;4:617-23.
52. Harbison RA, Kubik M, Konnick EQ, et al. The mutational landscape of recurrent versus nonrecurrent human papillomavirus-related oropharyngeal cancer. JCI Insight 2018;3:99327.
53. Karli K, Allison L, Teresa E, et al. Health disparities in veterans: a map of the evidence. Med Care 2017;55:S9-15.
54. Skolarus TA, Chan S, Shelton JB, et al. Quality of prostate cancer care among rural men in the veterans health administration. Cancer 2013;119:3629-35.
55. Gutt R, Malhotra S, Hagan MP, et al. Palliative radiotherapy within the veterans health administration: barriers to referral and timeliness of treatment. JCO Oncol Pract 2021;17:e1913-22.
56. Ambroggi M, Biasini C, Del Giovane C, Fornari F, Cavanna L. Distance as a barrier to cancer diagnosis and treatment: review of the literature. Oncologist 2015;20:1378-85.
57. De Virgilio A, Costantino A, Mercante G, et al. Present and future of de-intensification strategies in the treatment of oropharyngeal carcinoma. Curr Oncol Rep 2020;22:91.
58. Hargreaves S, Beasley M, Hurt C, Jones TM, Evans M. Deintensification of adjuvant treatment after transoral surgery in patients with human papillomavirus-positive oropharyngeal cancer: the conception of the PATHOS study and its development. Front Oncol 2019;9:936.
